Guidant Anticipating Less Volatility In Coronary Stent Market In 2000
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects its launch of the Tristar coronary stent later this year to further enhance the company's leading market share position.
You may also be interested in...
Is Stent Market Waning Or Just Beginning? Clinicians, Firms Offer Views
The coronary stent market seems to be maturing, as new product introductions offer fewer distinctions between successive product generations, according to clinicians.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.